Compare Liquidia Corporation Common Stock (LQDA) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liquidia Corporation Common Stock vs Xylem, Inc. — how do they compare? Liquidia Corporation Common Stock trades at $33.69 (market cap $2.40B), while Xylem, Inc. trades at $102.9 (market cap $23.94B). The key difference: Xylem, Inc. is far larger — about 10× Liquidia Corporation Common Stock's market cap, and Xylem, Inc. pays a 1.68% dividend while Liquidia Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Xylem, Inc. for 51 Days on average.
| LQDA | XYL | |
|---|---|---|
Market Cap | $2.40B | $23.94B |
Volume | 2,857,547 | 1,097,519 |
Sector | Health | Industrials |
52-Week High | $91.03 | $152.95 |
52-Week Low | $22.02 | $100.92 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $2.30B | $25.72B |
Dividend Yield | — | 1.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Xylem (XYL) trades at $102.74, showing modest daily gains of 0.15%. The stock demonstrates strong fundamental performance with consistent earnings beats and revenue growth from $5.5B in 2022 to $9.0B in 2025. Technical indicators signal bearish momentum despite neutral oscillators, with key support at $101. Recent developments include strategic acquisitions of Cornell Pump and Roper Pump, strengthening the company's industrial water solutions portfolio.
Xylem presents a compelling investment case with solid profitability (11.15% net margin) and analyst consensus target of $146.63 offering 43% upside potential. However, technical weakness and China market challenges pose near-term risks. The company's focus on water infrastructure and digital solutions positions it well for long-term growth in essential water technology markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Liquidia Corporation Common Stock
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
